Norway, Feb. 11 -- Zelluna, a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced a clinical partnership with Medpace, a leading global Contract Research Organization (CRO), to support the first clinical trial of ZI-MA4-1 (ZIMA-101), Zelluna's lead product candidate.Highlights: * Medpace selected as clinical partner for ZI-MA4-1 (ZIMA-101) first-in-human Phase 1 study * Comprehensive CRO services to support Zelluna's transition to clinical-stage company * Study to evaluate safety and early efficacy in patients with advanced solid cancers * Clinical data expected to emerge from mid-2026 * Marks first clinical evaluation of Zelluna's pro...